Counterpulsation Cardio

Counterpulsation therapy (EECP or ECP) is a safe, non-invasive, out-patient based treatment.
In the USA it has been approved for use by the Food and Drugs Administration (FDA) since 1995.
In 2013 it was recommended for use in refractory angina by the European Society of Cardiology.
In 2017 the Renew Tm NCP-5 External Counterpulsation cardiac bed was awarded the European Union level 2a medical device CE mark.
Almost any adult with a heart problem can have counterpulsation therapy and there is no upper age limit. It is particularly beneficial to cardiac patients who continue to experience angina following bypass surgery or stents. This is often called chronic stable angina. This happens because although the large vessels have been opened by angioplasty or blockages by-passed by surgery the microscopic vessels within the heart muscle are blocked, leading to a lack of oxygen which in turn causes chest pain.